SEARCH

SEARCH BY CITATION

References

  • Abshire, T. & Kenet, G. (2004) Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis, 2, 899909.
  • Agency of Health Care Policy and Research. (1992) Acute Pain Management: Operative or Medical Procedures and Trauma (Agency of Health Care Policy and Research Publications). Clinical Pharmacology, 11, 391414.
  • Aledort, L.M. (2004) Comparitive thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. Journal of Thrombosis and Haemostasis, 2, 17001708.
  • Aledort, L.M. (2005) Comparitive thrombotic event incidence after infusion of recombinant factor VIIa vs factor VIII inhibitor bypass activity – reply to a rebuttal. Journal of Thrombosis and Haemostasis, 3, 822.
  • Astermark, J., Berntorp, E., White, G.C. & Kroner, B.L. (2001) The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia, 7, 267272.
  • Batlle, J., Lopez, M.F. & Brackmann, H.H. (1999) Induction of immune tolerance with recombinant factor VIII in haemophilia A patients with inhibitors. Haemophilia, 5, 431435.
  • Baudo, F., De Cataldo, F. & Italian Association of Haemophilia Centres (AICI): Registry of acquired factor VIII inhibitors. (2003) Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. British Journal of Obstetrics and Gynaecology 113, 11314.
  • Berntorp, E. & Bjorkman, S. (2003) The pharmacokinetics of clotting factor therapy. Haemophilia, 9, 353359.
  • Berntorp, E., Donfield, S., Waters, J., Mattson, E., DiMichele, D.M., Gringeri, A. & Astermark, J. (2005) The FEIBA Novoseven Comparoitive study (FENOC) – a randomised evaluation of bypassing agents in haemophilia complicated by inhibitors. Blood, 106, 98a.
  • Bjorkman, S. & Berntorp, E. (2001) Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clinical Pharmacokinetics, 40, 815832.
  • Bjorkman, S. & Carlsson, M. (1997) The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications. Haemophilia, 3, 18.
  • Bjorkman, S., Shapiro, A. & Berntorp, E. (2001) Pharmacokinetics of recombinant factor IX in relation to age of the patients; implications for dosing in prophylaxis. Haemophilia, 7, 133139.
  • Blanchette, V., Shapiro, A., Liesner, R., Hernandez, F., Retzios, A.D., Schoth, P., Fritsch, S., Spotts, G. & Ewenstein, B.M. (2004) Characterisation of the pharmacokinetics of rFVIII in young pre-school children, including an analysis of the influence of age and body weight. Blood, 104, 842a, abstr 3084.
  • Brackmann, H.H., Oldenburg, J. & Swaab, R. (1996) Immune tolerance for the treatment of factor VIII inhibitors – twenty years of the Bonn protocol. Vox Sanguinis, 70, 3035.
  • Brackmann, H.H., Effenberger, E., Hess, R., Schwaab, R. & Oldenburg, J. (2000) Novoseven in immune tolerance therapy. Blood Coagulation and Fibrinolysis, 11(Suppl. 1), S39S44.
  • Bray, G.L., Gomperts, E.D., Courter, S., Gruppo, R., Gordon, E.M., Manco-Johnson, M., Shapiro, A., Scheibel, E., White, G. & Lee, M. (1994) A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 83, 24282435.
  • Carcao, M., St Louis, J., Poon, M.C., Grunebaum, E., Lacroix, S., Stain, A.M., Blanchette, V.S. & Rivard, G. (2004) Inhibitor Subcommittee of the Association of Hemophilia Clinic Directors of Canada. Rituximab for congenital hemophiliacs with inhibitors: a Canadian experience. Haemophilia, 12, 718.
  • Chavin, S.I., Siegel, D.M. & Rocco, T.A. (1988) Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor. American Journal of Medicine, 85, 244249.
  • Chistolini, A., Ghirardini, A. & Tirindelli, M.C. (1987) Inhibitor to factor VIII in a non-haemophilic patient: evaluation of the response to DDAVP and the in vitro kinetics of factor VIII. Neuve Revue Francaise Haematologie, 29, 221224.
  • Coller, B.S., Hultin, M.B., Hoyer, L.W., Miller, F., Dobbs, J.V., Dosik, M.H. & Berger, F.R. (1981) Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood, 58, 619624.
  • Collins, P., Macartney, N., Davies, R., Lees, S., Giddings, J. & Majer, R. (2004) A population based, unselected, consecutive cohort of patients with acquired haemophilia A. British Journal of Haematology, 124, 8690.
  • Collins, P.W., Baglin, T., Brown, S., Dolan, G., Hanley, J., Keeling, D., Liesner, R., Makris, M. & Hay, C. on behalf of UKHCDO. (2005) UKHCDO acquired haemophilia study: a complete national cohort. Blood, 106, 322 (abstr).
  • Delgardo, J., Jimenez-Yuste, V., Hernandez-Navarro, F. & Villar, A. (2003) Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. British Journal of Haematology, 121, 2135.
  • DiMichele, D.M. (2003) Immune tolerance therapy dose as an outcome predictor. Haemophilia, 9, 382386.
  • DiMichele, D.M., Kroner, B. & the North American Immune Tolerance Study Group. (2002) The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thrombosis and Haemostasis, 87, 5257.
  • Dykes, A.C., Walker, I.D., Lowe, G.D.O. & Tait, R.C. (2001) Combined prednisolone and intravenous immunoglobulin treatment for acquired factor VIII inhibitor: a 2-year study. Haemophilia, 7, 160163.
  • Ehrlich, H.J., Henzl, M.J. & Gomperts, E.D. (2002) Safety of factor VIII inhibitor bypass activity (FEIBA) 10-year compilation of thrombotic adverse events. Haemophilia, 8, 8390.
  • Ewenstein, B.M., Takemoto, C., Warrier, I., Lusher, J., Saidi, P., Eisle, J., Ettinger, L.J. & DiMichele, D.M. (1997) Nephrotic syndrome as a complication of immune tolerance in Hemophilia B. Blood, 89, 11151116.
  • Ewenstein, B.M., Joist, J.H., Shapiro, A.D., Hofstra, T.C., Leissinger, C.A., Seremetis, S.V., Broder, M., Mueller-Velten, G., Schwartz, B.A. & Mononine Comparison Study Group. (2002) Pharmacokinetic analysis of plasma derived and recombinant FIX concentrates in previously treated patients with moderate or severe haemophilia B. Transfusion, 42, 190197.
  • Ewing, N. & Kasper, C. (1982) In vitro detection of mild inhibitors to factor VIII in haemophilia. American Journal Clinical Pathology, 77, 793797.
  • Freedman, J., Rand, M.L., Russel, O., Davis, C., Cheatley, P.L., Blanchette, V. & Garvey, M.B. (2003) Immunoadsorption may provide a cost effective approach to management of patients with inhibitors to FVIII. Transfusion, 43, 15081513.
  • Gascoigne, E.W., Dash, C.H., Harman, C. & Wilmot, D. (2004) A retrospective survey on the safety of Replenine, a high purity factor IX concentrate. Pharmacoepidemiology and Drug Safety, 13, 187195.
  • Goudemand, J., Tagariello, G. & Lopaciuk, F. (2004) Cases of surgery in high-responder haemophilia patients. Haemophilia, 10(Suppl. 2), 4649.
  • Green, D. & Kwaan, C.H. (1987) An acquired factor VIII inhibitor responsive to high-dose gamma globulin. Thrombosis and Haemostasis, 57, 521522.
  • Green, D. & Lechner, K. (1981) A survey of 214 non-hemophilic patients with inhibitors to factor VIII. Thrombosis and Haemostasis, 45, 200203.
  • Green, P.M., Montandon, A.J., Bentley, D.R. & Giannelli, F. (1991) Genetics and molecular biology of haemophilias A and B. Blood Coagulation and Fibrinolysis, 2, 539565.
  • Green, D., Rademaker, A.W. & Briet, E. (1993) A prospective randomised trial of prednisolone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thrombosis and Haemostasis, 70, 753757.
  • Hart, H.C., Kraaijenhagen, R.J., Kerckhaert, J.A., Verdel, G. & Van De Wiel, A. (1988) A patient with a spontaneous factor VIII:C autoantibody: successful treatment with cyclosporin. Transplant Proceedings, 20(Suppl. 4), 323328.
  • Hauser, I., Schneider, B. & Lechner, K. (1995) Post-partum factor VIII inhibitors. Thrombosis and Haemostasis, 73, 15.
  • Hay, C.R.M. (2005) Inhibitors to factor VIII/IX: treatment of inhibitors – immune tolerance induction. In: Chapter 13 in Textbook of Hemophilia (ed. by C.A.Lee, E.E.Berntorp & W.K.Hoots), Blackwell, Oxford.
  • Hay, C.R. & Lee, C.A. (2002) Inhibitors. In: Inhibitors in Patients with Haemophilia (ed. by E.C.Roiguez-Merchan & C.A.Lee), Blackwell, Berlin.
  • Hay, C.R.M., Negrier, C. & Ludlam, C.A. (1997) The treatment of bleeding in acquired haemophilia with recombinant factor VIIa. Thrombosis and Haemostasis, 78, 14631467.
  • Hay, C.R., Ludlam, C.A., Colvin, B.T., Hill, F.G., Preston, F.E., Wasseem, N., Bagnall, R., Peake, I.R., Berntorp, E., Mauser Bunschoten, E.P., Fijnvanaat, K., Kasper, C.K., White, G. & Santagostino, E. (1998) Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thrombosis and Haemostasis, 79, 762766.
  • Hay, C.R., Baglin, T.P., Collins, P.W., Hill, F.G. & Keeling, D.M. (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). British Journal of Haematology, 111, 7890.
  • Hedner, U. (2004) Dosing with recombinant factor viia based on current evidence. Seminars in Hematology, 41(Suppl. 1), 3539.
  • Hilgartner, M., Makiperna, A. & Dimichele, D.M. (2003) Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia, 9, 261268.
  • Hilgartner, M.W., Knatterud, G.L. & the FEIBA study group. (1983) The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood, 61, 3640.
  • Keeling, D., Beavis, J. & Sukhu, K. (2005) A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B. British Journal Haematology, 128, 885.
  • Kenet, G., Lubetsky, A., Gitel, S., Luboshitz, J., Varon, D. & Martinowitz, U. (2000) Treatment of bleeding episodes in patients with hemophilia and an inhibitor: comparison of two treatment protocols with recombinant activated factor VII. Blood Coagulation Fibrinolysis, 11(Suppl. 1), S35S38.
  • Kenet, G., Lubetsky, A., Luboshitz, J. & Martinowitz, U. (2003) A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). Journal of Thrombosis and Haemostasis, 1, 450455.
  • Key, N.S., on behalf of the US rFVIIa Home Therapy Study Group (1998) Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (novoseven) in haemophiliacs with inhibitors. Thrombosis and Haemostasis, 80, 912918.
  • Kreuz, W., Ehrenforth, S., Funk, M., Auerswald, D., Mentzer, J., Joseph-Steiner, J., Beeg, T., Klarmann, D., Scharrer, I. & Kornhuber, B. (1995) Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up. Haemophilia, 1, 2432.
  • Kreuz, W., Mentzer, D., Auerswald, G., Becker, S. & Joseph-Steiner, J. (1996) Successful immunetolerance therapy of FVIII inhibitor in children after changing from high to intermediate purity FVIII concentrate. Haemophilia, 2(Suppl. 1), 19.
  • Kreuz, W., Escurich-Ettinghauser, C., Martinez, I., Mentzer, D., Figura, S. & Klarmann, D. (2000) Efficacy and safety of FVIII inhibitor bypassing activity (FEIBA) for long-term prophylaxis in patients with high-responding inhibitors. Blood, 96, 265a, abs 1140.
  • Kroner, B.L. (1999) Comparison of the international immune tolerance registry and the north American Immune tolerance registry. Vox sanguinis, 77, 3337.
  • Laffan, M., Brown, S.A., Collins, P.W., Cummin, A.M., Hill, F.G.H., Keeling, D.M., Peake, I.R. & Pasi, K.J. (2004) Diagnosis of Von Willebrand disease. A guideline from the UK Haemophilia Centre Doctors’ Organisation. Haemophilia, 10, 199217.
  • Lee, M., Poon, W.Y. & Kingdon, H. (1990) A two-phase linear regression model for biologic half-life data. Journal of Laboratory and Clinical Medicine, 115, 745748.
  • Lee, C.A., Barrowcliffe, T., Bray, G., Gomperts, E., Hubbard, A., Kemball-Cook, G., Lilley, P., Owens, D., Von Tilberg, L. & Pasi, J. (1996) Pharmacokinetic in vivo comparison using 1-stage and chromogenic substrate assays with two formulations of Hemofil-M. Thrombosis and Haemostasis, 76, 950956.
  • Lee, M., Morfini, M. & Schulman, S. (2001) The Design and Analysis of Pharmacokinetic Studies of Coagulation Factors. Factor VIII/IX SSC-ISTH 2001 Recommendations. WWW document. URL. http://www.med.unc.edu/isth/fviiipharmaco.htm.
  • Lian, E.C.Y., Larcada, A.F. & Chiu, A.Y.Z. (1989) Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Annals of Internal Medicine, 110, 774778.
  • Lian, E.C., Villar, M.J., Noy, L.I. & Ruiz-Dayao, Z. (2002) Acquired factor VIII inhibitor treated with cyclophosphamide, vincristine, and prednisone. American Journal of Hematology, 69, 294295.
  • Lloyd Jones, M., Wight, J., Paisley, S. & Knight, C. (2003) Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia, 9, 464520.
  • Lottenberg, R., Kentro, T.B. & Kitchens, C.S. (1987) A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Archives of Internal Medicine, 147, 10771081.
  • Ludlam, C.A., Smith, M.P., Morfini, M., Gringeri, A., Santagostino, E. & Savidge, G.F. (2003) A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. British Journal of Haematology, 120, 808813.
  • Lusher, J.M. (1994) Use of prothrombin complex concentrates in management of bleeding in hemophiliacs with inhibitors: benefits and limitations. Seminars in Haematology, 31(Suppl. 4), 4952.
  • Lusher, J.M., Shapiro, S.S., Palascak, J.E., Rao, A.V., Levine, P.H., Blatt, P.M. & the Haemophilia study group. (1980) Efficacy of prothrombin complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. New England Journal of Medicine, 303, 421425.
  • Lusher, J.M., Arkin, S., Abildgaard, C.F. & Schwartz, R.S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. New England Journal of Medicine, 328, 453459.
  • Lusher, J.M., Ingerslev, J., Roberts, H. & Hedner, U. (1998a) Clinical experience with recombinant factor VIIa. Blood Coagulation and Fibrinolysis, 9, 119128.
  • Lusher, J.M., Roberts, H.R., Davignon, G., Joist, J.H., Smith, H., Shapiro, A., Laurian, Y., Kasper, C.K., Mannucci, P.M. & the rFVIIa Study Group. (1998b) A randomised, double blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia, 4, 790798.
  • Lusher, J.M., Lee, C.A., Kessler, C.M. & Beosian, C.L. (2003) The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia, 9, 3849.
  • Mariani, G., Ghirardini, A. & Belloco, R. (1994) Immunetolerance in hemophilia. Principal results from the International Registry. Thrombosis and Haemostasis, 72, 155158.
  • Mathias, M., Khair, K., Hann, I. & Liesner, R. (2004) Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. British Journal of Haematology, 125, 366368.
  • Mauser-Bunschoten, E.P., Niewenhuis, H.K., Roosendaal, G. & Van Den Berg, H.M. (1995) Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood, 86, 983988.
  • McMillan, C.W., Shapiro, S.S., Whitehurst, D., Hoyer, L.W., Rao, A.V. & Lazerson, J. (1988) The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors. Blood, 71, 344348.
  • Mizon, P., Goudemand, J., Jude, B. & Marey, A. (1992) Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor. Annals of Haematology, 64, 309311.
  • Morfini, M. (2003) Pharmacokinetics of factor VIII and factor IX. Haemophilia, 9(Suppl. 1), 94100.
  • Morfini, M., Lee, M. & Messori, A. (1991) The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/IX standardisation Sub-Committee of the International Society for Thrombosis and Haemostasis. Thrombosis and Haemostasis, 66, 384386.
  • Morfini, M., Cinotti, A., Bellatreccia, A., Paladion, E., Gringeri, A., Mannuci, P.M. & the Refacto-AICE study group. (2003) A multicentre pharmacokinetic study of the B-domain deleted recombinant factor VIII concentrate using difference assays and standards. Journal of Haemostasis and Thrombosis, 1, 22832289.
  • Morrison, A.E., Ludlam, C.A. & Kessler, C. (1993) Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood, 81, 15131520.
  • Mudad, R. & Kane, W.H. (1993) DDAVP in acquired haemophilia A: case report and review of the literature. American Journal of Haematology, 43, 295299.
  • Negrier, C., Goudemand, J., Sultan, Y., Bertrand, M., Rothschild, C., Lauroua, P. & the members of the French FEIBA study group. (1997) Multicenter retrospective study on the utilisation of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thrombosis and Haemostasis, 77, 11131119.
  • Nemes, L. & Pitlik, E. (2003) Ten years experience with immune tolerance induction therapy in acquired hemophilia. Haematologica, 88(Suppl. 12), 106110.
  • Parameswaran, R., Shapiro, A.D., Gill, J.C., Kessler, C.M. & HTRS Registry Investigators. (2005) Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia, 11, 100106.
  • Pascual, B. & Montoro, J.B. (1997) Comparative study of four different pharmacokinetic computer programs: case study of a factor VIII preparation. European Journal of Clinical Pharmacology, 52, 5964.
  • Pasi, K.J., Collins, P.W., Keeling, D.M., Brown, S.A., Cumming, A.M., Dolan, G.C., Hay, C.R.M., Hill, F.G.H., Laffan, M. & Peake, I.R. (2004) Management of Von Willebrand disease. A guideline from the UK Haemophilia Centre Doctors’ Organisation. Haemophilia, 10, 218231.
  • Pfliegler, G., Boda, Z., Harsfalvi, J., Flora-Nagy, M., Sari, B., Pecze, K. & Rak, K. (1989) Cyclosporin treatment of a woman with acquired hemophilia due to factor VIII inhibitor. Postgraduate Medical Journal, 65, 400.
  • Rivard, G.E., St Louis, J., Lacroix, S., Champagne, M. & Rocks, G. (2003) Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution. Haemophilia, 9, 711716.
  • Rizza, C.R., Spooner, R.J. & Giangrande, P.L. (2001) Treatment of haemophilia in the United Kingdom 1981–1996. Haemophilia, 7, 349359.
  • Roberts, H.R., Monroe, D.M. III & Hoffman, M. (2004) Safety profile of recombinant factor VIIa. Seminars in Hematology, 41, 101108.
  • Rocino, A. & De Biasi, R. (1999) Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients. Vox Sanguinis, 81, 3538.
  • Rodriguez-Merchan, E.C., Wiedel Jd, J., Wallny, T., Hvid, I., Berntorp, E., Rivard, G.E., Goddard Nj, N., Querol, F. & Caviglia, H. (2003) Elective Orthopaedic Surgery for inhibitor patients. Haemophilia, 9, 625631.
  • Rothschild, C., Laurian, Y., Satre, E.P., Borel Derlon, A., Chambost, H., Moreau, P., Goudemand, J., Parquet, A., Peynet, J., Vicariot, M., Beurrier, P., Claeyssens, S., Durin, A., Faradji, A., Fressinaud, E., Gaillard, S., Guerin, V., Guerois, C., Pernod, G., Pouzol, P., Schved, J.F. & Gazengel, C. (1998) French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: incidence of inhibitor and evaluation of immune tolerance. Thrombosis and Haemostasis, 80, 779783.
  • Sallah, S. (2004) Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia, 10, 169173.
  • Santagostino, E., Gringeri, A. & Mannucci, P.M. (1999) Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention. British Journal of Haematology, 104, 2226.
  • Santagostino, E., Morfini, M., Rocino, A., Baudo, F., Scaraggi, F.A. & Gringeri, A. (2001) Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thrombosis and Haemostasis, 86, 954958.
  • Schneiderman, J., Nugent, D.J. & Young, G. (2004) Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia, 10, 347351.
  • Schulman, S. (1998) Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group. Haemophilia, 4, 564567.
  • Schulman, S., Langevitz, P., Livneh, A., Martinowitz, U., Seligsohn, U. & Varon, D. (1996) Cyclosporin therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thrombosis and Haemostasis, 76, 344346.
  • Schwartz, R.S., Gabriel, D.A., Aledort, L.M., Green, D. & Kessler, C.M. (1995) A prospective study of the treatment of acquired (autoimmune) factor VIII inhibitors with high dose intravenous gammaglobulin. Blood, 86, 797804.
  • Shapiro, A.D., Gilchrist, G.S., Hoots, W.K., Cooper, H.A. & Gastineau, D.A. (1998) Prospective, randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis Haemostasis, 80, 773778.
  • Shapiro, A.D., Di Paola, J., Cohen, A., Pasi, K.J., Heisel, M.A., Blanchette, V.S., Abshire, T.C., Hoots, W.K., Lusher, J.M., Negrier, C., Rothschild, C. & Roth, D.A. (2005) The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe haemophilia B. Blood, 105, 518525.
  • Sjamsoedin, L.J., Heijnen, L., Mauser-Bunschoten, E.P., Van Geijswijk, J.L., Van Houwelingen, H., Van Asten, P. & Sixma, J.J. (1981) The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with haemophilia A and antibodies to factor VIII. A double-blind clinical trial. New England Journal of Medicine, 305, 717721.
  • Smith, M.P., Spence, K.J., Waters, E.L., Berresford-Webb, R., Mitchell, M.J., Cuttler, J., Alhaq, S.A., Brown, A.A. & Savidge, G.F. (1999) Immune tolerance therapy for haemophilia A patients with acquired factor VIII antibodies: comprehensive analysis of experience at a single institution. Thrombosis and Haemostasis, 81, 3538.
  • Smith, M.P., Ludlam, C.A., Collins, P.W., Hay, C.R., Wilde, J.T., Grigeri, A., Melsen, T. & Savidge, G.F. (2001) Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thrombosis and Haemostasis, 86, 949953.
  • Stasi, R., Brunetti, M., Stipa, E. & Amadori, S. (2004) Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood, 103, 44244428.
  • Struillou, L., Fiks-Sigaud, M., Barrier, J.H. & Blat, E. (1993) Acquired haemophilia and rheumatoid arthritis: success of immunoglobulin therapy. Journal of Internal Medicine, 233, 304305.
  • Sultan, Y. (1992) Prevalence of inhibitors in a population of 3435 hemophilia patients in France. French Hemophilia Study Group. Thrombosis and Haemostasis, 67, 600602.
  • Sultan, Y., Kazatchkine, M.D., Caisonneuve, P. & Nydegger, U.E. (1984) Anti-idiotype suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous immunoglobulin. The Lancet, ii, 765768.
  • Tarantino, M.D., Collins, P.W., Hay, C.R., Shapiro, A.D., Gruppo, R.A., Berntorp, E., Bray, G.L., Tonetta, S.A., Schroth, P.C., Retzios, A.D., Rogy, S.S., Sensel, M.G., Ewenstein, B.M. & RAHF-PFM Clinical Study Group. (2004) Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia, 10, 428437.
  • Tjonnfjord, G.E. (2004) Activated prothrombin complex concentrate (FEIBA) Treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia, 10(Suppl. 2), 4145.
  • Turecek, P.L., Varadi, K., Gritsch, H. & Schwarz, H.P. (2004) FEIBA: mode of action. Haemophilia, 10(Suppl. 2), 39.
  • Varadi, K., Negrier, C., Berntorp, E., Astermark, J., Bordet, J.C., Morfini, M., Linari, S., Schwarz, H.P. & Turecek, P.L. (2003) Monitoring the bioavailability of FEIBA with a thrombin generation assay. Journal of Thrombosis and Haemostastis, 1, 23742380.
  • Warrier, I. (1998) Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia, 4, 574576.
  • Warrier, I., Lenk, H., Saidi, P., Pollman, H., Tengborn, L. & Berntorp, E. (1998) Nephrotic synome in hemophilia B patients with inhibitors. Haemophilia, 4, 248251.
  • White, G.C., Beebe, A. & Nielsen, B. (1997) Recombinant factor IX. Thrombosis and Haemostasis, 78, 261265.
  • White, G.C., Shapiro, A., Ragni, M., Garzone, P., Goodfellow, J., Tubridy, K. & Couter, S. (1998) Clinical evaluation of recombinant factor IX. Seminars in Hematology, 35(Suppl. 2), 3338.
  • Young, G., McDaniel, M. & Nugent, D.J. (2005) Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia, 11, 203207.
  • Zeitler, H., Ulrich-Merzenich, G., Hess, L., Konsek, E., Unkrig, C., Walger, P., Vetter, H. & Brackmann, H. (2005) Treatment of acquired hemophilia by the Bonn-Malmo protocol: documentation of an in vivo immunomodulating concept. Blood, 105, 22872293.